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Abstract
Background: The cross talk between RAGE and angiotensin II (AngII) activation may be important in the development of
atherosclerosis. Soluble RAGE (sRAGE), a truncated soluble form of the receptor, acts as a decoy and prevents the
inflammatory response mediated by RAGE activation. In this study, we sought to determine the effect of sRAGE in inhibiting
AngII-induced atherosclerosis in apolipoprotein E knockout mice (Apo E KO).
Methods and Results: 9 week old Apo E KO mice were infused subcutaneously with AngII (1 mg/min/kg) and saline for 4
weeks using osmotic mini-pumps. The mice were divided into 4 groups 1. saline infusion and saline injection; 2. saline
infusion and sRAGE injection; 3. AngII infusion and saline injection; 4. AngII infusion and sRAGE injection. Saline or 0.5 mg,
1 mg, to 2 mg/day/mouse of sRAGE were injected intraperitoneally daily for 28 days. We showed that atherosclerotic plaque
areas in the AngII-infused Apo E KO mice and markers of inflammation such as RAGE, ICAM-1, VCAM-1, and MCP-1 were
increased in aorta compared to that of the Apo E KO mice. However, the treatment of 0.5 mg, 1 mg, and 2 mg of sRAGE in
AngII group resulted in the dose-dependent decrease in atherosclerotic plaque area. We also demonstrated that sRAGE
decreased RAGE expression level as well as inflammatory cytokines and cell adhesion molecules in AngII or HMGB1 treated-
rat aorta vascular smooth muscle cells.
Conclusion: The results demonstrated that partical blockade of RAGE activation by sRAGE prevent AngII -induced
atherosclerosis. Therefore these results suggested that first, RAGE activation may be important in mediating AngII-induced
atherogenesis, and second, AngII activation is a major pathway in the development of atherosclerosis. Taken together,
results from this study may provide the basis for future anti- atherosclerotic drug development mediated through RAGE
activation.
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Introduction
Activation of the renin-angiotensin system (RAS)-signaling
pathway, through the activation of the NADPH oxidase system,
results in increased oxidative stress and vascular inflammation and
has a significant role in the pathogenesis of atherosclerosis.
Previous studies have shown that activation of RAS signaling is
associated with increased expression of the Receptor for Advanced
Glycation Endproducts (RAGE) at the site of vascular inflamma-
tion [1,2].
RAGE is an important endogenous pattern recognition receptor
important for initiation of innate immune responses, and is a
member of the immunoglobulin superfamily of cell surface
molecules specific for diverse endogenous ligands [3,4]. Activation
of RAGE by ligands such as HMGB1, S100A/calgranulin, and
advanced glycation end products is associated with induction of
oxidative stress, increased inflammatory cytokines, and recruit-
ment of proinflmmatory cells [5,6]. RAGE signaling has been
linked to various chronic inflammatory diseases such as diabetes,
atherosclerosis, and inflammatory renal disease [7,8]. Thus, the
increase in damaged self-proteins during the initiation of vascular
inflammation and atherogenesis may result in RAGE activation-
mediated inflammation. Angiotensin II (AngII), through activation
of NADPH oxidase, increases oxidative stress and vascular
inflammation and is known to accelerate the development of
atherosclerosis [9,10]. However, there have been no reports
regarding the role of RAGE during the progression of AngII-
PLOS ONE | www.plosone.org 1 August 2013 | Volume 8 | Issue 8 | e69669
mediated atherosclerosis. Prior studies have shown that infusion of
angiotensin II for 4 weeks in Apo E knockout mice is associated
with acceleration of atherosclerosis beyond that observed in
untreated Apo E knockout mice [11].
Therefore, in this study, we sought to determine the inhibitory
effect of soluble RAGE (sRAGE), a decoy receptor that blocks
RAGE activation and inhibits inflammatory responses mediated
by RAGE activation, in an AngII-induced atherosclerosis model
using Apolipoprotein E knockout (Apo E KO) mice.
Materials and Methods
Expression and Purification of sRAGE-Fc Fusion Protein
The purified mouse sRAGE-Fc fusion protein was purchased
from A&R Therapeutics (Daejeon, Republic of Korea) for the
experiment. Briefly, For the sRAGE-Fc construction, a leader
sequence (gene ID: K02149; protein: AAA51633); mouse IgG H
chain (primer set: 59-ATAGGCTAGCGCCACCATGG-
GATGG-39, 59-TGTGTGAGTTTTGTCCGAGTGGACA
TCTGT-39), a.a 23–341 of mouse sRAGE (primer set: 59-
GGTCAGAACATCA CAGCCCGG ATTG-39, 59-
TGTGTGAGTTTTGTCCCCCATGGTGCAAGA-39), and
the human IgG1 Fc region (primer set: 59-GGCTAGCGTACC-
CAGCCCAGACTC-39, 59-CCAGCTCGAGCTATT-
TACCCGGAGACAG-39) were amplified, and the overlap
extension PCR was performed. To express the desired domain,
PCR product was treated with SfiI and ligated into pYK 602-His
vector (vector constructed by KRIBB). To express the mRAGE-
Fc, Mouse sRAGE-Fc was transfected into HEK293E cells and
collected supernatants every other day. To purify, a protein A-
Sepharose column (Amersham Biosciences, Piscataway, NJ, USA)
was used according to the manufacturer’s instructions. The
purified recombinant sRAGE was dialyzed with PBS, analyzed
by SDS-PAGE. After quantification, mRAGE was aliquoted and
stored at 270uC for experiment. And analysis with the Limulus
amebocyte lysate test kit (Cape Cod, East Falmouth, MA, USA)
was performed to examine the endotoxin level.
Figure 1. Survival and Development of Atherosclerotic Lesions in Apo E KO mice with AngII-induced atherosclerosis. A. Survival
graph of Angiotensin II-induced atherosclerosis in Apo E KO mice with saline injection, AngII-infused, and AngII with sRAGE-treated groups. B.
Immunohistochemistry sections of aorta (left = ascending aorta, right = infrarenal abdominal aorta) staining for inflammation markers (RAGE, ICAM-1,
VCAM-1, and MCP-1) from Apo E KO mice saline injection and AngII-induced atherosclerotic Apo E KO mice (magnification: x10 and below RAGE data:
x20). C. Decreased intensity in atherosclerotic areas of sRAGE-treated AngII-induced Apo E KO mice compared to AngII-induced Apo E KO mice (n = 7).
The positive stain is expressed in arbitrary units normalized against a control. *p,0.01, Scale bar = 200 mm.
doi:10.1371/journal.pone.0069669.g001
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Figure 2. Quantification of Atherosclerotic Lesions. A. Development of atherosclerotic plaque areas in en face aortas (n = 7, representative
picture) stained with Oil Red-O stain from Apo E KO mice. B. The percent of atherosclerotic plaque area in the Apo E KO saline injection and in mice
that received infusions of AngII with or without various doses of sRAGE. Relative quantification (% plaque area) was performed. *p,0.05 and
**p,0.01.
doi:10.1371/journal.pone.0069669.g002
Figure 3. Quantification of Atherosclerosis. A. Photomicrographs of atherosclerotic lesions from aortic sinuses of Apo E KO saline injection mice,
AngII infused, and AngII infused with various doses of sRAGE (n = 7); scale bar, 200 mm. B. Quantitative data, *p,0.01.
doi:10.1371/journal.pone.0069669.g003
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Animal Studies
Apo E KO male mice on a C57BL/6J background were
obtained from the Jackson Laboratory (Bar Harbor, ME, USA)
and all animal experiments conformed to the Guide for the Care and
Use of Laboratory Animals that was published by the US National
Institute of Health (NIH Publication No. 8523, revised 1985). 9-
week-old Apo E KO mice were anaesthetized by intraperitoneally
injection of zoletil (30 mg/kg) and xylazine (10 mg/kg), and then
were infused subcutaneously with AngII (Sigma, St. Louis, USA)
at a concentration of 1 mg/min/kg and saline for 4 weeks using
osmotic mini-pumps (Alzet, model 2004; flow rate = 0.25 ml/
hour). Mice were divided into 4 groups: 1. saline infusion and
saline IP injection; 2. saline infusion and sRAGE IP injection
(A&R Therapeutics, Daejeon, Republic of Korea); 3. AngII
infusion and saline IP injection; 4. AngII infusion and sRAGE IP
injection. sRAGE was injected daily for 28 days and the
concentration of sRAGE varied from 0.5 mg, 1 mg, to 2 mg/day/
mouse for each group to determine dose responsiveness (N= 10 for
each groups).
After waiting for 28 days after the initial injection period, the
animals were sacrificed for the necessary analysis. The animals
were fed a standard diet ad libitum, had free access to water, and
were housed in a room with 12 hours of light/dark cycle with a
maintained temperature of 25uC for 9 weeks. All animal studies
and post-mortem procedures were approved by the Institutional
Animal Care and Use Committee of Yonsei University (Approval
reference number: 2010-0310, 2011-0008).
Determination of Blood Pressure
For the blood pressure determination, the mice that were used
from for the blood pressure measurement were exposed to the
same treatment protocol but were a separate group of mice from
the animals sacrificed for pathologic assessment and immunohis-
tochemical assessment. Briefly, 9-week-old Apo E KO mice were
anaesthetized by intraperitoneally injection of zoletil (30 mg/kg)
and xylazine (10 mg/kg), and then were infused subcutaneously
with AngII (Sigma, St. Louis, USA) at a concentration of 1 mg/
min/kg and saline for 4 weeks using osmotic mini-pumps (Alzet,
model 2004; flow rate = 0.25 ml/hour). Mice were divided into 3
groups: 1. saline infusion and saline IP injection (N= 7); 2. AngII
infusion and saline IP injection (N= 7); 3. AngII infusion and
2 mg/day of sRAGE IP injection for 28 days (N= 7). Systolic and
diastolic blood pressure was measured in live mice by a non-
invasive approach using a validated tail-cuff system that relies on
volume pressure recording technology (BP-2000, Visitech Systems,
Apex, NC, USA). Blood pressure was monitored on the 55th, 56th
day of the 8weeks experimental period. The chamber was kept at
35–36uC and the equipment was set for a maximum inflation
pressure of 180 mmHg. Mice were placed in the restrainers
several times before the measurements for acclimatization to the
environment. All mice were first acclimated to the blood pressure
measurements for 3 days (these data were discarded) and then the
blood pressure was determined as the average measurement of the
subsequent 2 days. For the blood pressure measurement protocol
on each day, after the initial acclimatization of the mice for five
cycles, the blood pressure was measured for 10 cycles and the
average measurement was derived.
Analysis of Atherosclerotic Lesion Area
Eight weeks after the AngII infusion, mice were anaesthetized
by intraperitoneal injection of zoletil (30 mg/kg) and xylazine
(10 mg/kg), and then hearts and aortas were perfused with
phosphate-buffered saline (PBS) by cardiac puncture. Hearts were
removed by cutting the ascending aorta and fixing in 4% (v/v)
formalin for at least 24 hours. Aortas were dissected from the
proximal ascending aorta and cut at the branch point. Adventitial
fat was removed from aorta. Fixed aortas were opened longitu-
dinally and stained with Oil Red-O solution for 12 hours, washed
Figure 4. Effect of sRAGE in Apo E KO mice on Expression of Cytokines and Adhesion Molecules. A-B. Apo E KO mice infused with AngII
were treated with various concentrations of sRAGE. Expressions of RAGE, ICAM-1 and MCP-1 were detected by western blot. The optical density is
expressed in arbitrary units normalized against b-actin control. Data in histograms represent mean6 SD from individual 3 experiments. Lane 1, saline
injection; lane 2, infusion of AngII; lane 3, infusion of AngII with 0.5 mg/day of sRAGE; lane 4, infusion of AngII with 1 mg/day of sRAGE; lane 5, infusion
of AngII with 2 mg/day of sRAGE, *p,0.01.
doi:10.1371/journal.pone.0069669.g004
The Effect of Soluble RAGE on Atherosclerosis
PLOS ONE | www.plosone.org 4 August 2013 | Volume 8 | Issue 8 | e69669
gently with distilled water, and photographed after pinning onto
silicone plates. Formalin-fixed hearts were embedded in OCT
compound (Leica biosystems, NUSSLOCH, Germany) and stored
at 280uC. Frozen heart tissue was cut into 10 mm sections
beginning with the lower portion of the heart until the aortic sinus
was visible, then placed on tissue section polysine-coated slides
(Thermo scientific, Hudson, NH, USA), and stained with Oil Red-
O for 12 hours, washed with distilled water briefly, and
Figure 5. Effects of sRAGE on mRNA Levels in Aorta of AngII-induced Apo E KOmice. A. Reverse transcription PCR analysis of RAGE, ICAM-
1 and MCP-1 gene expression. Data in histograms represent mean 6 SD from 3 experiments. Lane 1, saline injection; lane 2, infusion of AngII; lane 3,
infusion of AngII with 0.5 mg/day of sRAGE; lane 4, infusion of AngII with 1 mg/day of sRAGE; lane 5, infusion of AngII with 2 mg/day of sRAGE. B. RAGE,
ICAM-1 and MCP-1 mRNA expression level were determined by Real-Time PCR. Results are means 6 SD from 3 experiments each performed in
duplicate. *p,0.05, **p,0.01, *** p,0.001 and ns =non-significant.
doi:10.1371/journal.pone.0069669.g005
Figure 6. Effect of sRAGE in Rat Aorta Vascular Smooth Muscle Cells. Western blot analysis showing expression of A, RAGE inflammation
receptor protein, ICAM-1, MCP-1, and TNF-a; and B, Quantitative data from panel A. Expression of RAGE, ICAM-1, MCP-1, TNF-a, and b-actin were
detected by western blot. Lane 1, control; lane 2, AngII-treated for 24 hours (100 nM); lane 3, HMGB1 treated for 15 minutes (1 mg/ml); lane 4, AngII
plus HMGB1; lane 5, AngII plus HMGB1 and sRAGE (0.5 mg/ml); lane 6, AngII plus HMGB1 and sRAGE (1 mg/ml); lane 7, AngII plus HMGB1 and sRAGE
(2 mg/ml); lane 8, treatment with sRAGE alone at 2 mg/ml. The optical density is expressed in arbitrary units normalized against a control. Data in
histograms represent mean 6 SD from 3 experiments. *p,0.01 vs control, {p,0.01 vs lane 4, #p,0.01 vs lane 4, ns = non-significant.
doi:10.1371/journal.pone.0069669.g006
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photographed by microscopy. Lesional areas of whole aortas and
plaques of aortic sinuses were calculated using the Image J program
(National institutes of Health, USA; http://rsb.info.nih.gov/ij).
Oil Red-O stained plaques were imaged from seven different
animals, then data were averaged.
Immunohistochemistry
Mouse aortas were removed from the heart and placed into
PBS; adipose tissue was removed in situ. Segments of aortas were
fixed in 10% (v/v) formalin solution and immersed in OCT
compound, and stored at 280uC. Aorta cross sections (5 mm) were
cut at the ascending aorta and the infrarenal abdominal aorta (2–
3 mm below the renal artery) and incubated at 45uC for 12 hours
to allow tissue to adhere to the slide. To stain with anti-RAGE,
anti-MCP-1 (abcamH, Cambridge, UK), anti-ICAM-1, or anti-
VCAM-1(Santa Cruz Biotechnology Inc., USA), sections were
incubated with primary antibodies at 4uC for overnight, followed
by fixation in acetone at 220uC for 10 minutes. Primary
antibodies were used at1:100. Stained slides were washed in PBS
then incubated with biotinylated polyclonal secondary antibodies,
and the slides were visualized using 3,39-diaminobenzidine before
glycerol gelatin mounting (Sigma, St. Louis, USA). Stained slides
imaged from seven different animals were photographed by
microscopy and were analyzed using the Image J program
(National institutes of Health, USA; http://rsb.info.nih.gov/ij).
RNA Extraction from Mouse Aorta Tissues and Reverse
Transcription PCR
The expression levels of various genes were analyzed by reverse
transcription-polymerase chain reaction (RT-PCR). Mouse aortas
were removed from the heart and were stored in RNAlater Tissue
Protect solution (QIAGEN, Mainz, Germany). Total RNA was
isolated from aorta tissue using RNA isolation from the fibrous
tissue kit (QIAGEN, Mainz, Germany). Complementary DNA
(cDNA) was generated with the Reverse Transcription System
(Bioneer, Seoul, Republic of Korea) according to the manufac-
turer’s instructions. 1 mg of total RNA was reverse-transcribed in a
20 ml reaction, with cDNA pre-mixed and 0.5 mg oligo-(dT) 15
primer at 42uC for 5 minutes. The reaction was terminated by
heating at 90uC for 1 hour.
PCR was performed with the AccuPower PCR Premix
(Bioneer, Seoul, Republic of Korea) and amplification conditions
were as follows: reaction volume, 20 mL; primer, 10 pM; and
template genomic DNA 1 mg. PCR was carried out in a thermal
cycler using the following conditions: 95uC for 3 minutes, 95uC for
1 minute and then individual conditions for each gene. All PCR
products were separated by electrophoresis on 1% agarose gels
and visualized using staining with Gel-red (Biotium, Hayward,
CA, USA) by Gel-Doc (Bio-Rad, Hercules, CA, USA).
The mouse gene primer sequences used for PCR were:
mRAGE, forward 59-CCTGGGTGCTGGTTCTTGCTCT-39
and reverse 59-GATCTGGGTGCTCTTACGGTCC-39 (nucle-
otides 31–52 and 12091-230 in GenBank accession no. L33412);
mICAM-1, forward 59- GAGAGTGGACCCAACTGGAA-39
and reverse 59- CTTTGGGATGGTAGCTGGAA-39;
mVCAM-1, forward 59- CCCAAGGATCCAGAGATTCA-39
and reverse 59- ACGTCAGAACAACCGAATCC-39 [12];
mMCP-1, forward 59- GGCTCA GCCAGATGCAGTTAA-39
and reverse 59- GTGAATGAGTAGCAGCAGGTGAGT-39
(nucleotides 154–174 and 181–204 in GenBank Ref
NM011333); and mGAPDH, forward 59- AATGCATCCTG-
CACCACCAACTGC-39 and reverse 59- GGAGGCCATG-
TAGGCCATGAGGTC-39 [13]. All samples were measured in
triplicates for statistical analysis.
Quantitative Real-Time PCR
PCRs were performed on LightCyclerH480II System using the
LightCyclerH 480 SYBR green I master mix (Roche Diagnostics,
Mannheim, Germany) according to the manufacturer’s instruc-
tions. The reaction mixtures conditions were as follows: final
volume, 20 mL; cDNA, 500 ng;, 1 and forward and reverse
primer, 10 pM. After pre-incubation at 95uC for 10 minutes, we
performed 45 PCR cycles, each consisting of a denaturation step
(95uC for 10 seconds) and an annealing step (58uC for 25 seconds).
The intensity of the expression of each gene quantitated using
LightCyclerH480 Software 1.5.0 (Roche Diagnostics, Mannheim,
Germany). Values were expr essed in arbitrary units. Relative
Figure 7. Measurement of Mice Blood Pressure. A. The results from the mice tail systolic and B, diastolic blood pressure. Compared to group 1
and group 2 were associated with significant increase in the blood pressure but, between group 2 and group 3 was not significant. N = 7 for each
groups. *p,0.05, ns = non-significant.
doi:10.1371/journal.pone.0069669.g007
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values of mRNA levels were determined by that of GAPDH gene,
and expressed as fold change over the control.
The mouse gene primer sequences used for PCR were:
mRAGE, forward 59-AAC ACA GCC CCC ATC CAA-39, and
reverse, 59-GCT CAA CCA ACA GCT GAA TGC-39 [14];
mICAM-1, forward 59-CGC TGT GCT TTG AGA ACT GTG-
39 and reverse 59-ATA CAC GGT GAT GGT AGC GGA-39
[15]; mMCP-1, forward 59-CTG AAG CCA GCT CTC TCT
TCC T-39 and reverse 59-CAG GCC CAG AAG CAT GAC A-39
[16] and mGAPDH, forward 59-CAT GGC CTT CCG TGT
TCC TA-39and reverse 59-GCG GCA CGT CAG ATC CA-39
[17]. All samples were measured in triplicates for statistical
analysis.
Cell Culture and Treatment
Rat aorta vascular smooth muscle cells (VSMCs) were
purchased from Biobud (Seongnam-si, Gyeonggi-do, Republic of
Korea). Cells were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM; Hyclone, Thermo Fisher scientific Inc., USA)
containing 10% fetal bovine serum (FBS), Penicillin
(10,000 Units/mL) and Streptomycin (10,000 mg/mL) in a
humidified incubator at 37uC under an atmosphere of 5% CO2
and 95% air. All the experiments were performed with cells at the
6th passage and incubated for 24 hours in serum-free medium
before treatment. The cells were incubated with Ang II (100 nM)
or sRAGE (0.5, 1, 2 mg/ml) for 24 hours and followed by HMGB1
(1 mg/ml) for 15 minutes before the end of the incubation period.
Human recombinant HMGB1 was purchased from A&R Ther-
apeutics (Daejeon, Republic of Korea).
Western Blot Analysis
Mouse aortas were removed from the heart and homogenized
immediately and lysed with RIPA buffer (Biosesang, Seongnam-si,
Gyeonggi-do, Republic of Korea) containing a protease inhibitor
cocktail (Calbiochem, Darmstadt, Germany). Cells were washed
twice with cold PBS and lysed using the same buffer as aorta
tissues. The protein concentration was measured by bicinchoninic
acid protein assay. Equal amounts of total protein samples were
loaded and separated by 10%–12.5% sodium dodecyl sulfate-
polyacrylamide (SDS-PAGE) gel and electro-blotted to a poly-
vinylidene difluoride membrane. The membranes were blocked by
Tris-buffered saline-Tween 20 (TBS-T, 0.1% Tween 20) contain-
ing 10% non-fat dried milk at room temperature for 1 hour and
membranes were washed twice with TBS-T and anti-RAGE, anti-
ICAM-1, anti-MCP-1, or anti-TNF-a(abcamH, Cambridge, UK);
primary antibodies were incubated overnight at 4uC. Membranes
were then washed with TBS-T and incubated with horseradish
peroxidase-conjugated secondary antibody at room temperature
for 1 hour. Signals were visualized using enhanced chemilumi-
nescent detection (Millipore Corporation, Billerica, MA, U.S.A.).
All samples were measured in triplicates for statistical analysis.
Statistical Analysis
Data were expressed as the mean 6 SD. ANOVA with
Bonferroni’s correction were used to compare the means of two
numeric values. Data analyses were done with commercially
available GraphPad Prism 5 software. p-values,0.05 were
considered statistically significant.
Results
Infusion of AngII Accelerates Atherosclerosis
To assess the activation of AngII with or without sRAGE, we
generated an atherosclerosis model in Apo E KO mice over a
period of 8 weeks. Mortality in the AngII-infused Apo E KO mice
significantly higher compared to Apo E KO mice injected with
saline (p-value = 0.013). However, there was no significant
difference in mortality between Apo E KO mice injected with
saline and AngII-infused Apo E KO mice that received sRAGE
injection (p-value = 0.103). Although statistically non-significant,
there was a tendency for the sRAGE injection group to have better
survival compared to the angiotensin II infusion group (p-
value = 0.220) (Figure 1A).
To check whether activation of NF-kB associated cell adhesion
molecules and cytokines are associated with atherosclerosis
formation with AngII treatment, cell adhesion molecules and
cytokines were examined by immunohistochemistry in Apo E KO
mice under several conditions at both the ascending aorta and the
infrarenal abdominal aorta (Figure 1B). As activation of RAGE is
known to increase inflammation markers and adhesion molecules
[6], we chose representative cytokines and adhesion molecules for
assessment. Aortic arches for experiments were collected and
Cryo-sections were made for immunohistochemistry. Serial
sections were stained and analyzed to detect the following markers
of inflammation; RAGE, ICAM-1, VCAM-1, and MCP-1.
Inflammatory markers were markedly increased in AngII-infused
Apo E KO mice, whereas 2 mg of sRAGE injection was associated
with significant reduction in the expression of inflammatory
markers. Use of 0.5 mg or 1 mg of sRAGE also produced a
concentration-dependent reduction in these inflammatory markers
(Figure 1C).
sRAGE Prevents AngII-induced Atherosclerotic Plaque
Formation
As plaque formation is an important phenomenon in the
atherosclerotic progress, we examined lesion progression in the
aorta. Atherosclerotic lesion areas were markedly increased in
AngII-infused mice compared to untreated controls, but sRAGE
injection showed a marked reduction in atherosclerotic plaque
areas, which were detected by Oil Red-O staining of en face and
aortic sinuses (Figure 2 and 3). Oil Red-O staining of whole aortas
showed more than a 2.5-fold increase in the atherosclerotic plaque
area in AngII-infused Apo E KO mice compared to age-matched,
untreated Apo E KO animals. In contrast, treatment with 2 mg of
sRAGE resulted in a 70% decrease in the atherosclerotic plaque
area as compared to mice that received only AngII-infusion
(Figure 2). Quantitation of staining results is shown in Figure 2B.
We injected lower doses of sRAGE, and found that injection of
either 0.5 mg or 1 mg of sRAGE also resulted in a significant dose-
dependent reduction in atherosclerotic plaque area to approxi-
mately 50%and 60%of that seen in mice that received AngII,
respectively. Increased atherosclerosis was also distinct at the
aortic sinus in the AngII-infused group, in which the lesion area
was increased by over 12-fold compared to untreated Apo E KO
mice. The administration of sRAGE decreased the average lesion
area by 80% compared to the AngII-infused Apo E KO mice
(Figure 3A and 3B). These findings suggest that sRAGE inhibits
the development of AngII-mediated atherosclerosis.
sRAGE Decreases Expression of Inflammation Markers
and Adhesion Molecules
We next used whole aorta tissue lysates to measure the
representative protein expression and mRNA levels of proteins
as downstream targets of RAGE activation, such as the
inflammatory marker MCP-1 and adhesion molecule ICAM-1
(Figure 4 and 5). Western blotting showed increased expression of
RAGE, ICAM-1, and MCP-1 in AngII-infused Apo E KO mice.
The Effect of Soluble RAGE on Atherosclerosis
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Treatment with sRAGE significantly decreased inflammatory
markers in a concentration-dependent manner. In mice treated
with 2 mg/ml of sRAGE, there was a significant reduction in the
expression of RAGE, ICAM-1, and MCP-1 (Figure 4A and 4B).
Similar findings were also observed when RT-PCR (Figure 5A)
and quantitative Real-time PCR (Figure 5B) were performed for
the expression of RAGE, ICAM-1, and MCP-1in AngII-infused
Apo E KO mice with or without sRAGE. Protein and mRNA
expression data demonstrate that increased levels of inflammatory
markers induced by AngII can be significantly inhibited by RAGE
blockade.
sRAGE Decreases Inflammation in Rat Aorta Vascular
Smooth Muscle Cells
We first investigated whether sRAGE could inhibit expression
of RAGE protein levels in VSMCs treated with AngII or HMGB1.
Quantitative western blot analysis revealed that HMGB1 or AngII
upregulated RAGE expression respectively compared to control
VSMCs and HMGB1 with AngII showed a synergistic effect on
RAGE expression. However, 0.5–2 mg/ml of sRAGE significantly
decreased the AngII/HMGB1-induced RAGE expression by
approximately 1.3-fold. We next investigated the effects of sRAGE
on ICAM-1, MCP-1, and TNF-a protein levels. In agreement
with our previous results, 0.5–2 mg/ml of sRAGE blocked AngII-
induced activation of each of the above-mentioned markers by
approximately 1.5-fold (Figure 6A and 6B).
Association AngII and Blood Pressure
The results from the mice tail blood pressure at the 55,56th day
of experiment showed that compared to Apo E knockout mice
injected with saline (group 1), mice chronically infused with Ang
II(group 2) were associated with significant increase in the systolic
and diastolic blood pressure (*p,0.05). However, the systolic and
diastolic blood pressure between group 2 and mice infused with
AngII and injected with 2 mg/day of SRAGE (group 3) was not
significant.
Discussion
Activation of the renin-angiotensin-aldosterone (RAS) system is
important in the pathogenesis of cardiovascular disease. Evidence
from numerous basic and clinical studies has unequivocally
demonstrated the clinical benefit of blocking RAS activation on
improvement of the prognosis of cardiovascular disease [18,19].
Angiotensin II, through the activation of the NADPH oxidase,
may increase the degree of oxidative stress and vascular
inflammation, which contributes to the pro-atherogenic effect of
angiotensin II [20,21]. Studies have shown that infusion of
angiotensin II for 4 weeks in Apo E knockout mice is associated
with acceleration of atherosclerosis beyond that of the control Apo
E knockout mice [11]. Infusion of angiotensin II was also
associated with neointimal proliferation of the vessel wall
(Figure 1B) which was attenuated by sRAGE administration.
There are several studies to support this result, in which NADPH
oxidase inhibitor have been shown to suppress the angiotensin II
induced neointimal formation [22,23].
RAGE is a multi-ligand signal transduction receptor for AGEs,
HMGB1, and S100/calgranulin. This receptor is an important
mediator of innate immune responses to endogenous ligands, and
is thus, known as an alarmin [5,24]. RAGE activates inflammatory
cascades through a combination of NF-kB activation, increasing
reactive oxygen species, and promoting leukocyte recruitment as
an adhesion receptor [24]. Enhanced expression of RAGE has
been demonstrated in various chronic inflammatory diseases such
as diabetes, atherosclerosis, rheumatoid arthritis, and inflamma-
tory kidney disease [25]. Recently, a study by Ihara et al.
demonstrated that in diabetic Apo E knockout mice, there was
an increased expression of RAGE that was significantly suppressed
in diabetic Apo E knockout/Angiotensin II type 1 receptor
knockout mice [26]. Since RAGE expression is downregulated
after knockout of the angiotensin II type 1 receptor, it is
conceivable that angiotensin II activation will result in increased
RAGE expression and activity.
This is the first study, to our knowledge, to demonstrate that
inhibition of RAGE activation by administration of the RAGE
decoy receptor, sRAGE, results in a significant, dose-dependent
decrease in angiotensin II induced atherosclerosis formation and
improvement in 60 day survival. In this experiment, we used a
recombinant sRAGE-Fc fusion protein cloned from a mammalian
cell system. As previous studies have shown that soluble protein-Fc
fusion proteins dramatic increase in half-life of soluble protein [27]
we were able to demonstrate attenuation of atherosclerosis using a
much lower dose than previously described [28]. In another
published experiment, we have demonstrated the efficacy of 2 mg
of the same sRAGE-Fc fusion protein in attenuating lupus
nephritis in NZB-WF1 lupus nephritis mice model [29].
The novelty of this finding is the fact that angiotensin II infusion
was associated with markedly increased expression of RAGE in
the aortas of non-diabetic Apo E knockout mice. RAGE activation
is commonly associated with diabetes, a condition that is
connected with increased oxidative stress and inflammation. The
dose-dependent effects of sRAGE on inhibiting atherosclerosis
indicate that RAGE might be important in mediating angiotensin
II-induced progression of atherosclerosis. However, the mecha-
nism linking angiotensin II activation with RAGE activation is not
defined. We speculate that the increased oxidative stress and
inflammation associated with angiotensin II activation results in
leukocyte infiltration and cellular necrosis, which will result in
increased extracellular release of S100/calgranulin and HMGB1.
We showed that RAGE activation acts to increase the degree of
inflammation and upregulation of RAGE expression. Although
there is a report that S100B stimulates proliferation and migration
in vascular smooth muscle through RAGE-mDia1 interaction
[30], a mechanism to link angiotensin II activation with RAGE
expression is unclear at the present time. The results from our
immunohistochemical staining, western blot and RT-PCR anal-
yses demonstrated increased expression of RAGE, ICAM-1, and
MCP-1 in the aortas of angiotensin II-administered Apo E
knockout mice, all of which were significantly attenuated with
sRAGE administration. We also checked systolic and diastolic
blood pressure to demonstrate whether or not the effect of sRAGE
in AngII is related to regulation of blood pressure as blood
pressure could be a factor that could accelerate atherosclerosis
independent from the effect of angiotensin II [31]. Although AngII
significantly increased blood pressure compared to control, the
administration of sRAGE failed to decrease blood pressure when
compared to the AngII-infused mouse, suggesting that effects of
sRAGE for AngII is independent from blood pressure regulation
(Figure 7). Further, it is interesting to note the decreased
expression of RAGE was observed in the aortas of animals treated
with sRAGE. RAGE is a unique receptor in that it is positively
upregulated following ligand activation. As such, the inhibition of
RAGE activation by sRAGE may act to attenuate the expression
of RAGE as well as the expression of various chemokine and
adhesion molecules that are mediated by RAGE activation.
One of the limitations of this study was the fact that as sRAGE is
an indirect inhibitor of RAGE activation acting through binding of
RAGE ligands, we cannot rule out the possibility that inhibition of
The Effect of Soluble RAGE on Atherosclerosis
PLOS ONE | www.plosone.org 8 August 2013 | Volume 8 | Issue 8 | e69669
Toll-Like Receptor activation may have contributed to the results.
As TLR 2/4 activation can be mediated by RAGE ligands such as
HMGB1 [32], sRAGE is not a specific blocker of RAGE
activation as the administration of sRAGE may partially inhibit
TLR4 activation. This has been demonstrated in a previous
experiment demonstrating the efficacy of sRAGE in attenuating
atherosclerosis in RAGE KO mice [32]. However, we still believe
that sRAGE has a significant effect in blocking RAGE activation
because firstly, Liliensiek’s results are limited to adaptive immune
responses such as EAE or DTH models [33] and secondly,
increased expression of RAGE and inflammatory markers by
AngII were significantly reduced under sRAGE treatment in our
experiment (Fig. 1C). Further studies using RAGE blocking
antibodies or RAGE/Apo E double knockout mouse models will
be needed.
In conclusion, the results from this study suggest that RAGE
activation may be important in mediating AngII-induced athero-
sclerosis which was shown to be independent from blood pressure
elevation. In addition, as AngII activation is a major pathway in
the development of atherosclerosis, the results from this study may
provide the basis for future anti-atherosclerotic drug development
focused on targeted RAGE activation.
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